FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus
Commissioner Margaret Hamburg’s structural reorganization of FDA leaves the current leadership of the drug and biologic review centers intact but adds a new layer of management and accountability between the medical product center directors and the commissioner’s office.
You may also be interested in...
US FDA Commissioner intends to change agency's siloed structure and move reviewers into teams that will follow products pre- and post-market.
Rachel Sherman takes over a position that has not been filled permanently since Josh Sharfstein left in 2011.
While OCE has a lofty status, it has yet to gain a large cadre of staff.